The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time...
Turnout has grown its client base fivefold since announcing its seed round in September 2025, logging more than ten million...
Most falls occur in public spaces, but many detection systems work only within a small radius of the home. Personal...
Groundbreaking Disability Training as Landmark Rule Takes Effect June 17WASHINGTON, June 10, 2026 /PRNewswire/ -- After years of Paralyzed Veterans of...
CLEVELAND, June 10, 2026 (GLOBE NEWSWIRE) -- SPR® announced the publication of “Observations from the RESET Clinical Trial: A Post-Hoc...
New studies show DREAMS program boosts incomes, savings, and resilience in refugee communities across East Africa The IKEA Foundation has committed...
Builds on positive Phase I safety data and represents a key value-inflection milestone for the CompanyAdvances a potentially disease-modifying approach...
Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy Paris, June 10, 2026. Sanofi today...
82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement in MG-ADL observed in Phase...
– Successful End-of-Phase 2 meeting with FDA agreeing on key elements of the proposed Phase 3 design, including study population,...
HAMILTON, Ontario, June 08, 2026 (GLOBE NEWSWIRE) -- A newly released national report is calling for urgent, coordinated action to...
Recognition honors Sun Life's commitment to expanding health access through community-based investingWELLESLEY, Mass. and NEW YORK, June 4, 2026 /PRNewswire/...
VIENNA, Va., June 4, 2026 /PRNewswire/ -- The National Academy of Elder Law Attorneys (NAELA), the leading professional association dedicated...
Designation is supported by an exploratory analysis from the Phase 1b study showing that some children with SMA previously treated...
Majority of patients met the American College of Rheumatology improvement criteria (ACR70) response by Week 36 Single-dose of miv-cel delivered...
Majority of patients met the American College of Rheumatology improvement criteria (ACR70) response by Week 36 Single-dose of miv-cel delivered...
Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Phase 3 trial; Top-line...
Partnerships with the Medical University of South Carolina, Prisma Health, and the South Carolina Community Health Worker Association drive toward...
Partnerships with the Medical University of South Carolina, Prisma Health, and the South Carolina Community Health Worker Association drive toward...
Annual publication analyzes structural shifts reshaping claims management, includinglitigation, workforce transformation and evolving medical and vehicle challengesSAN DIEGO, June 2,...